Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FB101
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Sofinnova Partners
Deal Size : $38.0 million
Deal Type : Series A Financing
Details : Freya will advance the clinical development of its lead drug candidate, FB101, an investigational vaginal microbial immunotherapeutic, for the treatment of infertility in women with dysbiotic vaginal microbiota who are undergoing assisted reproductive te...
Brand Name : FB101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 12, 2023
Lead Product(s) : FB101
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Sofinnova Partners
Deal Size : $38.0 million
Deal Type : Series A Financing
Lead Product(s) : FB101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FB101, is an investigational vaginal microbial immunotherapeutic, which is investigated for the treatment of Women with Asymptomatic Vaginal Dysbiosis.
Brand Name : FB101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 27, 2023
Lead Product(s) : FB101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
